RESUMO
Melanin-concentrating hormone (MCH) is implicated in the feeding behavior in mammals affording a potential target to control overeating in people. Compound 1 (AMG 076) has been identified as a potent MCHr1 antagonist for the treatment of obesity. A synthesis suitable for the large-scale preparation of this lead candidate was developed to support preclinical studies. A Robinson annulation of benzylpiperidone and resolution of the desired enone from a mixture of the diastereomers afforded key intermediate 6 after a stereoselective hydrogenation. Subsequent Fischer indole synthesis with hydrazine 5 then provided the advanced intermediate, indole 2. Two complementary reductive amination strategies employing either aldehyde 3 or lactol 4 led to the synthesis of title compound 1.
Assuntos
Benzenossulfonatos/síntese química , Benzenossulfonatos/farmacologia , Ácidos Cicloexanocarboxílicos/síntese química , Ácidos Cicloexanocarboxílicos/farmacologia , Receptores de Somatostatina/antagonistas & inibidores , Benzenossulfonatos/química , Ácidos Cicloexanocarboxílicos/química , Humanos , Isoquinolinas/síntese química , Isoquinolinas/química , Estrutura Molecular , EstereoisomerismoRESUMO
The discovery of a series of potent, carboline-based MK2 inhibitors is described. These compounds inhibit MK2 with IC50s as low as 10 nM, as measured in a DELFIA assay. An X-ray crystal structure reveals that they bind in a region near the p-loop and the hinge region of MK2a.